Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Paratek Pharmaceuticals, Inc. (PRTK : NSDQ)
 
 • Company Description   
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.

Number of Employees: 208

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.97 Daily Weekly Monthly
20 Day Moving Average: 558,569 shares
Shares Outstanding: 54.48 (millions)
Market Capitalization: $107.32 (millions)
Beta: 1.57
52 Week High: $11.24
52 Week Low: $1.79
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.81% -7.75%
12 Week -47.61% -43.15%
Year To Date -56.13% -47.83%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
75 PARK PLAZA
-
BOSTON,MA 02116
USA
ph: 617-807-6600
fax: 617-275-0039
ir@paratekpharma.com http://www.paratekpharma.com
 
 • General Corporate Information   
Officers
Evan Loh - Chief Executive Officer and Director
Michael F. Bigham - Executive Chairman
Sarah Higgins - Vice President; Finance and Controller
Minnie V. Baylor Henry - Director
Thomas J. Dietz - Director

Peer Information
Paratek Pharmaceuticals, Inc. (CORR.)
Paratek Pharmaceuticals, Inc. (RSPI)
Paratek Pharmaceuticals, Inc. (CGXP)
Paratek Pharmaceuticals, Inc. (BGEN)
Paratek Pharmaceuticals, Inc. (GTBP)
Paratek Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 699374302
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 54.48
Most Recent Split Date: 10.00 (0.08:1)
Beta: 1.57
Market Capitalization: $107.32 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.71 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 0.77
EPS Growth
vs. Year Ago Period: 10.26%
vs. Previous Quarter: 45.31%
Sales Growth
vs. Year Ago Period: 51.34%
vs. Previous Quarter: -21.81%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -32.77
12/31/21 - -33.52
09/30/21 - -28.35
Current Ratio
03/31/22 - 4.62
12/31/21 - 4.86
09/30/21 - 5.25
Quick Ratio
03/31/22 - 4.18
12/31/21 - 4.51
09/30/21 - 4.95
Operating Margin
03/31/22 - -42.31
12/31/21 - -45.39
09/30/21 - -43.25
Net Margin
03/31/22 - -42.31
12/31/21 - -45.39
09/30/21 - -45.32
Pre-Tax Margin
03/31/22 - -41.88
12/31/21 - -44.93
09/30/21 - -45.32
Book Value
03/31/22 - -2.58
12/31/21 - -2.62
09/30/21 - -2.15
Inventory Turnover
03/31/22 - 2.20
12/31/21 - 2.05
09/30/21 - 1.73
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©